Randomised trials of second-line treatment of small cell lung cancer
| Regimen | Year | Phase | Patients n | Response rate % | TTPweeks | Survival weeks | [Ref.] | |||
| OR | CR | PR | SD | |||||||
| CAV versus topotecan | 1999 | II | 104/107 | 18/24 | 1/0 | 17/24 | 12/20 | –/– | 25/25 | 71 |
| Topotecan, oral versus intravenous | 2001 | II | 52/54 | 23/15 | 2/4 | 21/11 | 19/30 | 15/13 | 32/25 | 75 |
| Topotecan, oral versus intravenous | 2007 | III | 155/154 | 18/22 | 1/0 | 17/22 | 18/23 | 12/15 | 33/35 | 74 |
| Oral topotecan/BSC versus BSC alone | 2006 | III | 71/70 | 7/– | 0/– | 7/– | 44/– | 16/– | 26/14 | 73 |
Time to progression (TTP) and survival are presented as medians. OR: overall response; CR: complete response; PR: partial response; SD: stable disease; CAV: cyclophosphamide, doxorubicin and vincristine; BSC: best supportive care.